Thyroid hormone replacement after radioiodine treatment for thyroid cancer
Observes thyroid hormone pills in adults with thyroid cancer after stopping hormones before radioiodine.
Plain-language title generated from the registry record
Registry title: Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy
Key facts
- Where
- Groningen and Nijmegen, NetherlandsSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06647602, who can take part
Where in Netherlands
- University Medical Center Groningen (UMCG)Groningen, NetherlandsNo longer taking part
- Radboud University NijmegenNijmegen, NetherlandsNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Medical Center Groningen
- Trial code
- NCT06647602EU 2024-511668-10-00
- Record updated
- 10 February 2026
- Original description
This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.Read full original descriptionShow less
Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy
This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.
Inclusion: Histologically confirmed DTC (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma); Classified as high-risk DTC according to the ATA guidelines or, patients for whom the risk of a recurrence is estimated to be higher based on clinical features (assessed by their treating physician); Prepared for RAI-therapy with TH-withdrawal; Patients must be fit to adhere to the study protocol; Patients must be able to read and understand the Dutch language.
Exclusion: Patients using proton-pomp inhibitors; Patients with comorbidities, such as severe heart failure, (poorly controlled) atrial fibrillation, of which the treating physician decides that L-T3 is unsuitable; Conditions or drugs interfering with thyroid hormone uptake:; Patients with a history of atrophic gastritis; Pregnancy.